ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IMV IMV Inc

1.12
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
IMV Inc TSX:IMV Toronto Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.12 0.60 0.70 0 01:00:00

IMV Inc. to Present at Upcoming Investor Conferences

14/05/2019 10:05pm

Business Wire


IMV (TSX:IMV)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more IMV Charts.

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in May:

RBC Capital Markets Global Healthcare Conference

  • Date: Tuesday, May 21, 2019
  • Time: 1:35 p.m. ET
  • Location: The InterContinental New York Barclay Hotel, New York, NY

National Bank Financials’ 9th Annual Quebec Conference

  • Date: Wednesday, May 29, 2019
  • Time: 9:50 a.m. ET
  • Location: Museum Room, Shangri-la Hotel, Toronto, Ontario

China Bio-Partnering Forum

  • Date: Thursday, May 30, 2019
  • Time: 1:40 p.m. CT
  • Location: Renaissance Schaumburg Convention Center Hotel, Chicago, IL

A copy of each meeting’s presentation will be available in the events and presentations section of IMV’s website. A live webcast of IMV’s presentation at the RBC Capital Markets conference will also be available and archived for 90 days on the events and presentations webpage.

About IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. Connect at www.imv-inc.com.

Investor Relations:Marc Jasmin, IMV Senior Director, Investor Relations and CommunicationsO: (902) 492-1819 ext : 1042M: (514) 617-9481 E: mjasmin@imv-inc.com

Media:Andrea Cohen, Sam Brown Inc.T: (917) 209-7163 E: andreacohen@sambrown.com

1 Year IMV Chart

1 Year IMV Chart

1 Month IMV Chart

1 Month IMV Chart

Your Recent History

Delayed Upgrade Clock